Please login to the form below

Not currently logged in
Email:
Password:

The Partners

This page shows the latest The Partners news and features for those working in and with pharma, biotech and healthcare.

Lynparza set for further expansion with EU approval in breast cancer

Lynparza set for further expansion with EU approval in breast cancer

The randomised, open label trial produced median progression-free survival improvement of 2.8 months (7.0 months for Lynparza vs. ... The partners also recently declared a further collaboration with diagnostics specialist firm Myriad.

Latest news

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    Exit also frees up $700m equity investment. Sanofi is bowing out of a five-year-old R&D alliance with Alnylam on rare disease therapies, but the partners will continue to ... The latest announcement ends the R&D phase of the collaboration, which means

  • Otsuka’s Alzheimer’s agitation drug hits the mark Otsuka’s Alzheimer’s agitation drug hits the mark

    pathology in Alzheimer’s – but nevertheless does address one of the most challenging symptoms in dementia care. ... The two partners are only releasing top-line findings from the phase 3 trial at the moment, with a second pivotal trial due to

  • Biogen and Eisai pull plug on Alzheimer’s drug Biogen and Eisai pull plug on Alzheimer’s drug

    The news has also hit Biogen’s share price, which has plunged by 25%. ... The partners have a similar candidate, BAN2401, being studied in prodromal and mild Alzheimer’s patients, though its future must now also be under review.

  • Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022 Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

    The two partners say they are also considering another phase 3 trial in even earlier-stage subjects that they describe as having ”preclinical” AD – in other words some signs of the ... amyloid changes in the brain that characterise the disease but

  • Biogen strikes $800m deal to buy gene therapy firm Nightstar Biogen strikes $800m deal to buy gene therapy firm Nightstar

    entry into ophthalmology,” according to the company’s CEO Michel Vounatsos (pictured below). ... The two partners had been working together on an XLRP candidate but AGTC is now progressing that independently.

More from news
Approximately 1 fully matching, plus 561 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    AC Immune and its partners are far from the only drug developers to target tau. ... By Nick Taylor, journalist specialising in the life sciences industry. 21st March 2019.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Funding for EPAD from IMI comes to an end in late 2019, but now that the infrastructure is in place, the partners hope to continue the initiative for many years to ... Successful projects may then be considered for licensing to industrial partners to

  • The importance of co-creation with patients The importance of co-creation with patients

    Use the expertise of people who have worked with patients as partners before. ... patients are brought on board as partners; from sharing their insights to collaborating on solutions, the barriers are worth overcoming.

  • Unlocking the potential of science and technology in the UK Unlocking the potential of science and technology in the UK

    The UK has one of most productive health and life sciences sectors in the world. ... The two partners have invested £360m of capital, property and intellectual assets into the new venture, with a business plan supporting the creation of over 20, 000 high

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    In the process, the focus on demonstrating value has now reached fever pitch. ... The value story. Beyond finding the right partners to unlock a clear understanding of shared value, one of the biggest challenges the industry faces is around how it

More from intelligence
Approximately 0 fully matching, plus 79 partially matching documents found.

Latest appointments

  • Dr Martin Rothman joins Sofinnova Partners Dr Martin Rothman joins Sofinnova Partners

    Rothman brings 40 years of experience along with an international network in the medical field to Sofinnova Partners. ... Commenting on the appointment, Antoine Papiernik, managing partner and chairman of Sofinnova Partners, said: “Martin is an

  • Unlimited Group appoints group managing director Unlimited Group appoints group managing director

    Richards joins the group from VCCP, where he held the role of international managing director. ... Richards will head the group’s partners’ board and will report into the group Chairman Ian Ferguson.

  • PureTech Health appoints new chief financial officer PureTech Health appoints new chief financial officer

    Joep Muijrers joins the biopharma from Life Sciences Partners. Clinical-stage biopharmaceutical company PureTech Health has bolstered the team with a new chief financial officer in the form of Joep Muijrers. ... Muijrers most recently served as a partner

  • Professor Carole Longson moves from NICE to the ABPI Professor Carole Longson moves from NICE to the ABPI

    and the role our members play in developing new innovative medicines and vaccines. ... experience, expertise and network in both industry and academia will enable the ABPI to work with our partners to further these objectives.”.

  • Lexington Communications bolsters team with a trio of new-hires Lexington Communications bolsters team with a trio of new-hires

    of the ever-changing health landscape to provide invaluable strategic advise and insider analysis to our existing and potential clients.”. ... Our new senior advisors will join a team that has the reputation of being one of the best in the market, and

More from appointments
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 62 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics